Rachel Abou Mrad

Rachel Abou Mrad practices at Rockefeller Neuroscience Institute - Neurology - HOPD in Morgantown, West Virginia.

Rachel Abou Mrad's NPI, 1386029213, was assigned on July 21, 2015. Rachel Abou Mrad holds West Virginia license 28470.

Rachel Abou Mrad's primary practice is Rockefeller Neuroscience Institute - Neurology - HOPD, at 33 Medical Center Dr, Morgantown, WV 26505.

Rachel Abou Mrad's primary practice is Rockefeller Neuroscience Institute - Neurology - HOPD in Morgantown, West Virginia. Rachel Abou Mrad is also affiliated with J.W. Ruby Memorial Hospital. The medical group on file is University Health Associates. Dmand AI also links Rachel Abou Mrad to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Rachel Abou Mrad practices, 3 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Rachel Abou Mrad's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Rachel Abou Mrad is licensed in West Virginia.

CMS data shows 116 Medicare services from Rachel Abou Mrad across 4 procedure codes in 2024, for 107 Medicare patients. Medicare paid $9,562 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 107 Medicare patients who saw Rachel Abou Mrad in 2024. The largest group is 65 to 74, with 64 patients. 75% of them have high cholesterol, and 73% have high blood pressure. 16% are also on Medicaid. Their average risk score is 1.54, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Rachel Abou Mrad's median patient age at 57, with 50% women.

In 2024, Rachel Abou Mrad wrote 136 Medicare Part D claims for 49 patients. 84% of them were for generic drugs. CMS names the drug for 58 of them, across 4 drugs with 11 or more claims each, at $462 in total drug cost. In 2023, CMS named 62 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Rachel Abou Mrad for performance year 2024, reported through an alternative payment model (APM). Rachel Abou Mrad accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Rachel Abou Mrad as offering telehealth.

Colonoscopy: 1 to 10 procedures (CMS shows small counts as a range)

Upper gastrointestinal (GI) endoscopy for acid reflux: 1 to 10 procedures (CMS shows small counts as a range)

CMS Open Payments shows 4 general payments to Rachel Abou Mrad from 4 drug and device companies from 2018 to 2025. Food and beverage make up the largest share, 100% of the total. AstraZeneca Pharmaceuticals LP paid the most, $105.